Next Article in Journal
Radiation and Anti-Cancer Vaccines: A Winning Combination
Previous Article in Journal
Development of Zika Virus Vaccines
Article Menu

Export Article

Open AccessReview
Vaccines 2018, 6(1), 8;

Challenges and Achievements in Prevention and Treatment of Smallpox

Department of Infectious Diseases, Israel Institute for Biological Research, P.O. Box 19, Ness-Ziona 74100, Israel
Author to whom correspondence should be addressed.
Received: 11 December 2017 / Revised: 15 January 2018 / Accepted: 26 January 2018 / Published: 29 January 2018
Full-Text   |   PDF [258 KB, uploaded 29 January 2018]


Declaration of smallpox eradication by the WHO in 1980 led to discontinuation of the worldwide vaccination campaign. The increasing percentage of unvaccinated individuals, the existence of its causative infectious agent variola virus (VARV), and the recent synthetic achievements increase the threat of intentional or accidental release and reemergence of smallpox. Control of smallpox would require an emergency vaccination campaign, as no other protective measure has been approved to achieve eradication and ensure worldwide protection. Experimental data in surrogate animal models support the assumption, based on anecdotal, uncontrolled historical data, that vaccination up to 4 days postexposure confers effective protection. The long incubation period, and the uncertainty of the exposure status in the surrounding population, call for the development and evaluation of safe and effective methods enabling extension of the therapeutic window, and to reduce the disease manifestations and vaccine adverse reactions. To achieve these goals, we need to evaluate the efficacy of novel and already licensed vaccines as a sole treatment, or in conjunction with immune modulators and antiviral drugs. In this review, we address the available data, recent achievements, and open questions. View Full-Text
Keywords: smallpox; vaccine; vaccinia; postexposure; MVA; LC16m8; Cidofovir; Tecovirimat; VIG; poly(I:C) smallpox; vaccine; vaccinia; postexposure; MVA; LC16m8; Cidofovir; Tecovirimat; VIG; poly(I:C)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Melamed, S.; Israely, T.; Paran, N. Challenges and Achievements in Prevention and Treatment of Smallpox. Vaccines 2018, 6, 8.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top